Portman Ltd’s PhenomeX Inc. Common Stock CELL Stock Holding History

Portman Ltd’s Portfolio CELL Stock Details CELL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-41,022	Closed	-$746K	–	13
2021 Q4	$746K	Buy	+41,022	New	+$885K	0.72%	10

Other funds holding CELL

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

SUT

SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return

Portman Ltd's CELL Position: Q1 2022 in Review

Portman Ltd sold out of PhenomeX Inc. Common Stock (CELL) in Q1 2022, closing a stake of 41,022 shares — an estimated $746K sold.

Portman Ltd first reported a position in CELL in Q4 2021 and held it in 1 quarter. The position peaked at $746K in Q4 2021. 130 funds tracked by Wall St. Rank hold CELL as of Q1 2022.

Portman Ltd reported no remaining PhenomeX Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Portman Ltd sold 41,022 PhenomeX Inc. Common Stock shares in Q1 2022, an estimated $746K.
Portman Ltd first reported a position in PhenomeX Inc. Common Stock in Q4 2021 and held it in 1 quarter.
Portman Ltd's PhenomeX Inc. Common Stock position peaked at $746K in Q4 2021.
130 funds tracked by Wall St. Rank held PhenomeX Inc. Common Stock as of Q1 2022.

Based on Portman Ltd's 13F filing for Q1 2022, filed 2 May 2022.